Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

O. Rosmorduc · SciRah

Researcher profile · Semantic Scholar

O. Rosmorduc

Share profile

O. Rosmorduc — researcher profile on SciRah

h-index: 49
Works: 155
Citations: 17K

Most-cited papers

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
J. Bruix, S. Qin, P. Merle, A. Granito +20 more
2017The Lancet3,268 citations Open access
Semantic Scholar
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
A. Zhu, R. Finn, J. Edeline, S. Cattan +55 more
2018The Lancet Oncology2,090 citations
Semantic Scholar
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
T. Yau, Joong-Won Park, R. Finn, A. Cheng +23 more
2021The Lancet Oncology930 citations
Semantic Scholar
CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
T. Yau, J.-W. Park, R. Finn, A. Cheng +16 more
2019Annals of Oncology620 citations Open access
Semantic Scholar
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
Andrew X. Zhu, O. Rosmorduc, T. R. Jeffry Evans, P. Ross +10 more
2015Journal of Clinical Oncology540 citations Open access
Semantic Scholar
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
D. Malka, P. Cervera, S. Foulon, T. Trarbach +21 more
2014The Lancet Oncology391 citations Open access
Semantic Scholar
Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
C. Verslype, O. Rosmorduc, P. Rougier
2012Annals of Oncology380 citations Open access
Semantic Scholar
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
J. Ricke, H. Klümpen, H. Amthauer, I. Bargellini +12 more
2019Journal of Hepatology337 citations Open access
Semantic Scholar
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
R. Finn, P. Merle, A. Granito, Yi-Hsiang Huang +13 more
2018Journal of Hepatology318 citations
Semantic Scholar
Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease.
O. Rosmorduc, C. Housset
2010Seminars in liver disease (Print)219 citations
Semantic Scholar
Detection of Hepatocellular Carcinoma with PET/CT: A Prospective Comparison of 18F-Fluorocholine and 18F-FDG in Patients with Cirrhosis or Chronic Liver Disease
J. Talbot, L. Fartoux, S. Balogova, V. Nataf +6 more
2010Journal of Nuclear Medicine199 citations Open access
Semantic Scholar
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.
M. Blivet-Van Eggelpoe L, Hamza Chettouh, L. Fartoux, L. Aoudjehane +6 more
2012Journal of Hepatology169 citations
Semantic Scholar
Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors
E. De Martin, J. Michot, O. Rosmorduc, C. Guettier +1 more
2020JHEP Reports167 citations Open access
Semantic Scholar
Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma
C. Desbois-Mouthon, A. Baron, M. Blivet-Van Eggelpoe L, L. Fartoux +4 more
2009Clinical Cancer Research149 citations Open access
Semantic Scholar
Genotype‐phenotype relationships in the low‐phospholipid‐associated cholelithiasis syndrome: A study of 156 consecutive patients
R. Poupon, O. Rosmorduc, P. Böelle, Y. Chrétien +4 more
2013Hepatology141 citations
Semantic Scholar
The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study
M. Lewin, L. Fartoux, A. Vignaud, L. Arrivé +2 more
2011European Radiology136 citations
Semantic Scholar
Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors.
Hamza Chettouh, L. Fartoux, L. Aoudjehane, D. Wendum +10 more
2013Cancer Research121 citations Open access
Semantic Scholar
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
M. Moehler, Jeong Heo, H. Lee, W. Tak +33 more
2019Oncoimmunology120 citations Open access
Semantic Scholar
Temporal trends, clinical patterns and outcomes of NAFLD‐related HCC in patients undergoing liver resection over a 20‐year period
R. Pais, L. Fartoux, C. Goumard, O. Scatton +3 more
2017Alimentary Pharmacology and Therapeutics120 citations Open access
Semantic Scholar
Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study.
A. Zaanan, N. Williet, M. Hebbar, T. S. Dabakuyo +8 more
2013Journal of Hepatology108 citations
Semantic Scholar
Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial.
J. Edeline, F. Bonnetain, J. Phelip, J. Watelet +16 more
201794 citations
Semantic Scholar
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
M. Munteanu, D. Tiniakos, Q. Anstee, F. Charlotte +66 more
2016Alimentary Pharmacology and Therapeutics89 citations Open access
Semantic Scholar
Aspects of liver pathology in adult patients with MDR3/ABCB4 gene mutations
D. Wendum, V. Barbu, O. Rosmorduc, L. Arrivé +2 more
2012Virchows Archiv76 citations
Semantic Scholar
A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial.
D. Malka, T. Trarbach, L. Fartoux, J. Mendiboure +6 more
2009Journal of Clinical Oncology60 citations
Semantic Scholar
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
M. Peck-Radosavljevic, T. Greten, J. Lammer, O. Rosmorduc +3 more
2010European Journal of Gastroenterology and Hepathology59 citations
Semantic Scholar
Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib
D. Waldschmidt, P. Merle, A. Granito, Y.-H. Huang +17 more
2018Zeitschrift für Gastroenterologie - German Journal of Gastroenterology51 citations
Semantic Scholar
LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
B. Sangro, Joong-Won Park, R. Finn, A. Cheng +16 more
202049 citations Open access
Semantic Scholar
LBA-03Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial
J. Bruix, P. Merle, A. Granito, Y.-H. Huang +16 more
201648 citations Open access
Semantic Scholar
Search: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients with Hepatocellular Carcinoma (HCC)
A. Zhu, O. Rosmorduc, J. Evans, P. Ross +6 more
201248 citations Open access
Semantic Scholar
The impact of combining Selective Internal Radiation Therapy (SIRT) with Sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The Soramic trial palliative cohort
J. Ricke, B. Sangro, H. Amthauer, I. Bargellini +10 more
201844 citations
Semantic Scholar
Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group.
J. Spano, I. Poizot-Martin, D. Costagliola, F. Boué +13 more
2016Annals of Oncology40 citations Open access
Semantic Scholar
HCC and NASH: how strong is the clinical demonstration?
O. Rosmorduc, L. Fartoux
2012Clinics And Research in Hepatology and Gastroenterology40 citations
Semantic Scholar
Combined features of low phospholipid‐associated cholelithiasis and progressive familial intrahepatic cholestasis 3
R. Poupon, V. Barbu, P. Chamouard, D. Wendum +2 more
2010Liver international (Print)40 citations Open access
Semantic Scholar
Prevalence of low phospholipid-associated cholelithiasis in young female patients.
B. Condat, D. Zanditenas, V. Barbu, M. Hauuy +11 more
2013Digestive and Liver Disease38 citations
Semantic Scholar
KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
A. Zhu, R. Finn, S. Cattan, J. Edeline +16 more
201836 citations
Semantic Scholar
Hepatocellular Carcinomas With Mutational Activation of Beta Catenin Require Choline and can be Detected by Positron Emission Tomography.
Angélique Gougelet, C. Sartor, Nadia Senni, J. Calderaro +14 more
2019Gastroenterology35 citations Open access
Semantic Scholar
Hepatobiliary anomalies associated with ABCB4/MDR3 deficiency in adults: a pictorial essay
J. Benzimra, S. Derhy, O. Rosmorduc, Y. Menu +2 more
2013Insights into Imaging34 citations Open access
Semantic Scholar
Targeting STAT3 in hepatocellular carcinoma: sorafenib again….
O. Rosmorduc, C. Desbois-Mouthon
2011Journal of Hepatology31 citations Open access
Semantic Scholar
Early Versus Late Hepatocellular Carcinoma Recurrence After Transplantation: Predictive Factors, Patterns, and Long-term Outcome
Nada El-domiaty, F. Saliba, E. Vibert, V. Karam +13 more
2020Transplantation30 citations
Semantic Scholar
Growth factor receptor binding protein 14 inhibition triggers insulin‐induced mouse hepatocyte proliferation and is associated with hepatocellular carcinoma
Lucille Morzyglod, M. Caüzac, Lucie Popineau, Pierre-Damien Denechaud +13 more
2017Hepatology30 citations Open access
Semantic Scholar
Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
A. Zhu, Yoon-Koo Kang, O. Rosmorduc, T. R. Jeffry Evans +7 more
2016Clinical Cancer Research29 citations Open access
Semantic Scholar
Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT).
Gaël S. Roth, L. Verlingue, M. Sarabi, Jean-Frédéric Blanc +30 more
2024European Journal of Cancer26 citations Open access
Semantic Scholar
Liver Resection for Early Hepatocellular Carcinoma: Preoperative Predictors of Non Transplantable Recurrence and Implications for Treatment Allocation.
M. Gelli, M. Sebagh, R. Porcher, E. Romanelli +7 more
2020Annals of Surgery26 citations
Semantic Scholar
Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial
P. Galle, R. Finn, P. Merle, A. Granito +14 more
2017Zeitschrift für Gastroenterologie - German Journal of Gastroenterology24 citations
Semantic Scholar
A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection
L. Fartoux, S. Balogova, V. Nataf, K. Kerrou +3 more
2012Nuclear medicine communications24 citations
Semantic Scholar
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82)
A. Vienot, M. Jacquin, M. Rebucci-Peixoto, Dimitri Pureur +20 more
2023BMC Cancer22 citations Open access
Semantic Scholar
Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment
C. Rolfo, N. Isambert, Antoine Italiano, L. Molife +13 more
2020British Journal of Clinical Pharmacology22 citations Open access
Semantic Scholar
Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: Final analysis of a randomized phase II trial (BINGO).
D. Malka, L. Fartoux, V. Rousseau, T. Trarbach +13 more
201222 citations
Semantic Scholar
Early and resectable HCC: Definition and validation of a subgroup of patients who could avoid liver transplantation
O. Scatton, C. Goumard, F. Cauchy, L. Fartoux +7 more
2015Journal of Surgical Oncology21 citations
Semantic Scholar
BIOSHARE multicenter neoadjuvant phase 2 study: Results of pre-operative sorafenib in patients with resectable hepatocellular carcinoma (HCC)—From GERCOR IRC.
Mohamed Bouattour, L. Fartoux, O. Rosmorduc, O. Scatton +15 more
201617 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Fartoux×17
Invite
L. Fartoux — researcher profile on SciRah
D. Wendum×8
Invite
D. Wendum — researcher profile on SciRah
P. Merle×7
Invite
P. Merle — researcher profile on SciRah
M. Kudo×7
Invite
M. Kudo — researcher profile on SciRah

×7

Invite

R. Finn — researcher profile on SciRah

Invite

J. Bruix — researcher profile on SciRah

Invite

A. Cheng — researcher profile on SciRah

Invite

M. Le Berre — researcher profile on SciRah

G. Meinhardt×6

Invite

G. Meinhardt — researcher profile on SciRah

Invite

J. Edeline — researcher profile on SciRah

Invite

E. Assenat — researcher profile on SciRah

Invite

B. Sangro — researcher profile on SciRah